Just saw something interesting and relevant while
Post# of 148282
(I haven't tried to figure out the picture inlay thing so I'm just going to type out what was on their slide)
KP415 Updates
* Held KP415 NDA late-cycle review meeting with FDA on Dec 1, 2020
* FDA re-affirmed KP415 PDUFA date of Mar 2, 2021, no safety or efficacy issues were raised
* Next step is confidential review/negotiation of draft label
So you see, once a drug is about to gain approval there needs to be some confidential negotiations around labeling. I know that to be true in my heart but it's nice to see a company confirm that it goes down like that. Makes me feel even more confident about what's happening behind the scenes with CYDY.
Yours truly,
Daytime Respert